Cabergoline for Prolactin: Dosing, Benefits, and Side Effects

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Cabergoline is a potent dopamine agonist primarily used to treat hyperprolactinemia, a condition characterized by elevated prolactin levels. It effectively suppresses prolactin secretion, restoring hormonal balance and alleviating associated symptoms like reduced libido, erectile dysfunction, and menstrual irregularities. Understanding its dosing, benefits, and potential side effects is crucial for safe and effective use.

Cabergoline for Prolactin: Dosing, Benefits, and Side Effects

Cabergoline (brand name Dostinex) is a potent dopamine agonist widely used in clinical practice to treat hyperprolactinemia, a condition characterized by abnormally high levels of the hormone prolactin. By mimicking the action of dopamine, Cabergoline effectively suppresses prolactin secretion from the pituitary gland, thereby restoring hormonal balance and alleviating the myriad symptoms associated with elevated prolactin. Understanding its precise dosing, therapeutic benefits, and potential side effects is crucial for safe and effective patient management.

Mechanism of Action:

Cabergoline is a long-acting dopamine D2 receptor agonist. It binds to D2 receptors on lactotroph cells in the anterior pituitary gland, inhibiting the synthesis and release of prolactin. Its high affinity for these receptors and prolonged half-life (approximately 63-69 hours) allow for less frequent dosing compared to other dopamine agonists like Bromocriptine.

Indications and Benefits:

The primary indication for Cabergoline is hyperprolactinemia, regardless of its cause. This includes:

• Prolactinomas: Benign tumors of the pituitary gland that produce excessive prolactin. Cabergoline is highly effective in shrinking these tumors and normalizing prolactin levels, often serving as the first-line treatment.
• Idiopathic Hyperprolactinemia: Elevated prolactin without an identifiable cause.
• Drug-Induced Hyperprolactinemia: Caused by medications that interfere with dopamine pathways (e.g., antipsychotics, certain antidepressants).

The therapeutic benefits of normalizing prolactin levels with Cabergoline are significant:

• Restoration of Sexual Function: In men, this includes improved libido, resolution of erectile dysfunction, and normalization of ejaculation. In women, it can restore libido and alleviate dyspareunia.
• Normalization of Reproductive Function: In women, it can restore regular menstrual cycles and ovulation, improving fertility. In men, it can improve sperm parameters.
• Resolution of Galactorrhea: Cessation of inappropriate milk production in both men and women.
• Reduction of Tumor Size: For prolactinomas, Cabergoline can lead to significant tumor shrinkage, often obviating the need for surgery.
• Improved Bone Mineral Density: Chronic hyperprolactinemia can lead to reduced bone density; normalizing prolactin can help improve this.

Dosing and Administration:

Cabergoline dosing is highly individualized and depends on the patient's prolactin levels, the underlying cause of hyperprolactinemia, and tolerability. It is typically initiated at a low dose and gradually titrated upwards. Common starting doses are:

• 0.25 mg once or twice weekly.

The dose can be increased by 0.25 mg per week every 4 weeks, or as directed by a physician, until the optimal therapeutic effect is achieved (i.e., prolactin levels normalize). The maximum recommended dose is typically 1 mg twice weekly, though higher doses may be used in refractory cases under strict medical supervision. Cabergoline should be taken with food to minimize gastrointestinal side effects.

Side Effects:

While generally well-tolerated, Cabergoline can cause side effects, particularly during initiation or dose escalation. The most common include:

• Gastrointestinal: Nausea (up to 27%), constipation (up to 15%), abdominal pain, dyspepsia.
• Neurological: Headache (up to 26%), dizziness (up to 19%), fatigue (up to 17%), somnolence.
• Psychiatric: Insomnia, depression, and rarely, impulse control disorders (e.g., pathological gambling, hypersexuality), especially at higher doses.
• Cardiovascular: Orthostatic hypotension (low blood pressure upon standing) can occur, particularly with the first few doses. Rarely, long-term use of high doses (typically >2 mg/week, often seen in Parkinson's disease treatment) has been associated with cardiac valvulopathy, necessitating regular cardiac monitoring in such cases. For hyperprolactinemia, the doses are generally much lower, and this risk is significantly reduced.

Patients should be counseled on potential side effects and advised to report any concerning symptoms to their healthcare provider. Gradual dose titration and taking the medication with food can help mitigate many adverse effects. Regular monitoring of prolactin levels and clinical symptoms is essential to ensure optimal treatment and minimize risks.